BOSTON SCIENTIFIC CORP (BSX.DE) Fundamental Analysis & Valuation

FRA:BSX • US1011371077

Current stock price

55.15 EUR
+3.38 (+6.53%)
Last:

This BSX.DE fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

8

1. BSX.DE Profitability Analysis

1.1 Basic Checks

  • In the past year BSX was profitable.
  • In the past year BSX had a positive cash flow from operations.
  • Each year in the past 5 years BSX has been profitable.
  • BSX had a positive operating cash flow in each of the past 5 years.
BSX.DE Yearly Net Income VS EBIT VS OCF VS FCFBSX.DE Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 1B 2B 3B 4B

1.2 Ratios

  • BSX has a better Return On Assets (6.64%) than 77.05% of its industry peers.
  • BSX has a Return On Equity of 11.96%. This is in the better half of the industry: BSX outperforms 78.69% of its industry peers.
  • Looking at the Return On Invested Capital, with a value of 8.70%, BSX is in the better half of the industry, outperforming 72.13% of the companies in the same industry.
  • The Average Return On Invested Capital over the past 3 years for BSX is below the industry average of 10.31%.
  • The last Return On Invested Capital (8.70%) for BSX is above the 3 year average (7.70%), which is a sign of increasing profitability.
Industry RankSector Rank
ROA 6.64%
ROE 11.96%
ROIC 8.7%
ROA(3y)5.27%
ROA(5y)4.17%
ROE(3y)9.54%
ROE(5y)7.64%
ROIC(3y)7.7%
ROIC(5y)7.08%
BSX.DE Yearly ROA, ROE, ROICBSX.DE Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 10 20 30

1.3 Margins

  • Looking at the Profit Margin, with a value of 14.44%, BSX belongs to the top of the industry, outperforming 86.89% of the companies in the same industry.
  • In the last couple of years the Profit Margin of BSX has grown nicely.
  • BSX's Operating Margin of 19.92% is amongst the best of the industry. BSX outperforms 81.97% of its industry peers.
  • BSX's Operating Margin has improved in the last couple of years.
  • With an excellent Gross Margin value of 69.01%, BSX belongs to the best of the industry, outperforming 80.33% of the companies in the same industry.
  • BSX's Gross Margin has been stable in the last couple of years.
Industry RankSector Rank
OM 19.92%
PM (TTM) 14.44%
GM 69.01%
OM growth 3Y6.86%
OM growth 5Y16.97%
PM growth 3Y41.81%
PM growth 5YN/A
GM growth 3Y0.01%
GM growth 5Y1.13%
BSX.DE Yearly Profit, Operating, Gross MarginsBSX.DE Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 20 40 60

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

5

2. BSX.DE Health Analysis

2.1 Basic Checks

  • BSX has a Return on Invested Capital (ROIC), which is just above the Cost of Capital (WACC), which means it is creating some value.
  • BSX has more shares outstanding than it did 1 year ago.
  • Compared to 5 years ago, BSX has more shares outstanding
  • The debt/assets ratio for BSX has been reduced compared to a year ago.
BSX.DE Yearly Shares OutstandingBSX.DE Yearly Shares OutstandingYearly Shares Outstanding 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 500M 1B
BSX.DE Yearly Total Debt VS Total AssetsBSX.DE Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 10B 20B 30B 40B

2.2 Solvency

  • An Altman-Z score of 3.83 indicates that BSX is not in any danger for bankruptcy at the moment.
  • The Altman-Z score of BSX (3.83) is better than 70.49% of its industry peers.
  • BSX has a debt to FCF ratio of 3.13. This is a good value and a sign of high solvency as BSX would need 3.13 years to pay back of all of its debts.
  • BSX has a Debt to FCF ratio of 3.13. This is in the better half of the industry: BSX outperforms 72.13% of its industry peers.
  • BSX has a Debt/Equity ratio of 0.46. This is a healthy value indicating a solid balance between debt and equity.
  • BSX has a Debt to Equity ratio of 0.46. This is comparable to the rest of the industry: BSX outperforms 47.54% of its industry peers.
Industry RankSector Rank
Debt/Equity 0.46
Debt/FCF 3.13
Altman-Z 3.83
ROIC/WACC1.08
WACC8.08%
BSX.DE Yearly LT Debt VS Equity VS FCFBSX.DE Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 0 5B 10B 15B 20B

2.3 Liquidity

  • BSX has a Current Ratio of 1.62. This is a normal value and indicates that BSX is financially healthy and should not expect problems in meeting its short term obligations.
  • BSX's Current ratio of 1.62 is in line compared to the rest of the industry. BSX outperforms 49.18% of its industry peers.
  • BSX has a Quick Ratio of 1.08. This is a normal value and indicates that BSX is financially healthy and should not expect problems in meeting its short term obligations.
  • Looking at the Quick ratio, with a value of 1.08, BSX is in line with its industry, outperforming 45.90% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 1.62
Quick Ratio 1.08
BSX.DE Yearly Current Assets VS Current LiabilitesBSX.DE Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2B 4B 6B 8B

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

7

3. BSX.DE Growth Analysis

3.1 Past

  • BSX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 21.51%, which is quite impressive.
  • BSX shows a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 26.01% yearly.
  • BSX shows quite a strong growth in Revenue. In the last year, the Revenue has grown by 19.88%.
  • The Revenue has been growing by 15.16% on average over the past years. This is quite good.
EPS 1Y (TTM)21.51%
EPS 3Y20.34%
EPS 5Y26.01%
EPS Q2Q%14.29%
Revenue 1Y (TTM)19.88%
Revenue growth 3Y16.54%
Revenue growth 5Y15.16%
Sales Q2Q%15.9%

3.2 Future

  • BSX is expected to show quite a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 13.13% yearly.
  • Based on estimates for the next years, BSX will show a quite strong growth in Revenue. The Revenue will grow by 10.46% on average per year.
EPS Next Y14.33%
EPS Next 2Y13.76%
EPS Next 3Y13.36%
EPS Next 5Y13.13%
Revenue Next Year10.74%
Revenue Next 2Y10.45%
Revenue Next 3Y10.28%
Revenue Next 5Y10.46%

3.3 Evolution

  • The estimated forward EPS growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
  • The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
BSX.DE Yearly Revenue VS EstimatesBSX.DE Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 10B 20B 30B 40B
BSX.DE Yearly EPS VS EstimatesBSX.DE Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 2 4 6

More info and screens

Find the best growth stocksShow best growing peers

5

4. BSX.DE Valuation Analysis

4.1 Price/Earnings Ratio

  • BSX is valuated rather expensively with a Price/Earnings ratio of 21.29.
  • Based on the Price/Earnings ratio, BSX is valued a bit cheaper than the industry average as 72.13% of the companies are valued more expensively.
  • The average S&P500 Price/Earnings ratio is at 27.66. BSX is valued slightly cheaper when compared to this.
  • Based on the Price/Forward Earnings ratio of 18.61, the valuation of BSX can be described as rather expensive.
  • 60.66% of the companies in the same industry are more expensive than BSX, based on the Price/Forward Earnings ratio.
  • Compared to an average S&P500 Price/Forward Earnings ratio of 38.00, BSX is valued rather cheaply.
Industry RankSector Rank
PE 21.29
Fwd PE 18.61
BSX.DE Price Earnings VS Forward Price EarningsBSX.DE Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 10 20 30

4.2 Price Multiples

  • BSX's Enterprise Value to EBITDA ratio is in line with the industry average.
  • 62.30% of the companies in the same industry are more expensive than BSX, based on the Price/Free Cash Flow ratio.
Industry RankSector Rank
P/FCF 26.37
EV/EBITDA 18.63
BSX.DE Per share dataBSX.DE EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 5 10

4.3 Compensation for Growth

  • The PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a correct valuation of the company.
  • BSX has an outstanding profitability rating, which may justify a higher PE ratio.
  • BSX's earnings are expected to grow with 13.36% in the coming years. This may justify a more expensive valuation.
PEG (NY)1.49
PEG (5Y)0.82
EPS Next 2Y13.76%
EPS Next 3Y13.36%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. BSX.DE Dividend Analysis

5.1 Amount

  • BSX does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

BSX.DE Fundamentals: All Metrics, Ratios and Statistics

BOSTON SCIENTIFIC CORP

FRA:BSX (4/22/2026, 3:41:52 PM)

55.15

+3.38 (+6.53%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)02-04
Earnings (Next)04-22
Inst Owners94.54%
Inst Owner ChangeN/A
Ins Owners0.16%
Ins Owner ChangeN/A
Market Cap81.96B
Revenue(TTM)20.07B
Net Income(TTM)2.90B
Analysts84.88
Price Target86.84 (57.46%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly Dividend0
Dividend Growth(5Y)N/A
DP0%
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)2.84%
Min EPS beat(2)1.62%
Max EPS beat(2)4.06%
EPS beat(4)4
Avg EPS beat(4)4.68%
Min EPS beat(4)1.62%
Max EPS beat(4)10.56%
EPS beat(8)8
Avg EPS beat(8)5.56%
EPS beat(12)12
Avg EPS beat(12)5.7%
EPS beat(16)15
Avg EPS beat(16)4.38%
Revenue beat(2)1
Avg Revenue beat(2)0.04%
Min Revenue beat(2)-0.88%
Max Revenue beat(2)0.96%
Revenue beat(4)3
Avg Revenue beat(4)0.87%
Min Revenue beat(4)-0.88%
Max Revenue beat(4)2.43%
Revenue beat(8)7
Avg Revenue beat(8)1.73%
Revenue beat(12)11
Avg Revenue beat(12)2.08%
Revenue beat(16)13
Avg Revenue beat(16)1.59%
PT rev (1m)-4.62%
PT rev (3m)-20.29%
EPS NQ rev (1m)-0.17%
EPS NQ rev (3m)-0.45%
EPS NY rev (1m)-0.28%
EPS NY rev (3m)-0.43%
Revenue NQ rev (1m)-0.1%
Revenue NQ rev (3m)-0.5%
Revenue NY rev (1m)-0.16%
Revenue NY rev (3m)-0.62%
Valuation
Industry RankSector Rank
PE 21.29
Fwd PE 18.61
P/S 4.8
P/FCF 26.37
P/OCF 21.27
P/B 3.98
P/tB N/A
EV/EBITDA 18.63
EPS(TTM)2.59
EY4.7%
EPS(NY)2.96
Fwd EY5.37%
FCF(TTM)2.09
FCFY3.79%
OCF(TTM)2.59
OCFY4.7%
SpS11.48
BVpS13.86
TBVpS-0.61
PEG (NY)1.49
PEG (5Y)0.82
Graham Number28.4169 (-48.47%)
Profitability
Industry RankSector Rank
ROA 6.64%
ROE 11.96%
ROCE 10.46%
ROIC 8.7%
ROICexc 9.17%
ROICexgc 30.32%
OM 19.92%
PM (TTM) 14.44%
GM 69.01%
FCFM 18.22%
ROA(3y)5.27%
ROA(5y)4.17%
ROE(3y)9.54%
ROE(5y)7.64%
ROIC(3y)7.7%
ROIC(5y)7.08%
ROICexc(3y)7.95%
ROICexc(5y)7.36%
ROICexgc(3y)27.25%
ROICexgc(5y)24.65%
ROCE(3y)9.26%
ROCE(5y)8.51%
ROICexgc growth 3Y16.23%
ROICexgc growth 5Y30.87%
ROICexc growth 3Y13.89%
ROICexc growth 5Y25.4%
OM growth 3Y6.86%
OM growth 5Y16.97%
PM growth 3Y41.81%
PM growth 5YN/A
GM growth 3Y0.01%
GM growth 5Y1.13%
F-Score7
Asset Turnover0.46
Health
Industry RankSector Rank
Debt/Equity 0.46
Debt/FCF 3.13
Debt/EBITDA 2.08
Cap/Depr 64.04%
Cap/Sales 4.36%
Interest Coverage 12.54
Cash Conversion 84.48%
Profit Quality 126.23%
Current Ratio 1.62
Quick Ratio 1.08
Altman-Z 3.83
F-Score7
WACC8.08%
ROIC/WACC1.08
Cap/Depr(3y)61.91%
Cap/Depr(5y)57.64%
Cap/Sales(3y)4.69%
Cap/Sales(5y)4.67%
Profit Quality(3y)127.68%
Profit Quality(5y)132.57%
High Growth Momentum
Growth
EPS 1Y (TTM)21.51%
EPS 3Y20.34%
EPS 5Y26.01%
EPS Q2Q%14.29%
EPS Next Y14.33%
EPS Next 2Y13.76%
EPS Next 3Y13.36%
EPS Next 5Y13.13%
Revenue 1Y (TTM)19.88%
Revenue growth 3Y16.54%
Revenue growth 5Y15.16%
Sales Q2Q%15.9%
Revenue Next Year10.74%
Revenue Next 2Y10.45%
Revenue Next 3Y10.28%
Revenue Next 5Y10.46%
EBIT growth 1Y30.81%
EBIT growth 3Y24.54%
EBIT growth 5Y34.7%
EBIT Next Year24.39%
EBIT Next 3Y16.29%
EBIT Next 5Y14.81%
FCF growth 1Y38.35%
FCF growth 3Y57.4%
FCF growth 5Y29.98%
OCF growth 1Y32.03%
OCF growth 3Y43.76%
OCF growth 5Y24.63%

BOSTON SCIENTIFIC CORP / BSX.DE Fundamental Analysis FAQ

What is the ChartMill fundamental rating of BOSTON SCIENTIFIC CORP (BSX.DE) stock?

ChartMill assigns a fundamental rating of 6 / 10 to BSX.DE.


What is the valuation status for BSX stock?

ChartMill assigns a valuation rating of 5 / 10 to BOSTON SCIENTIFIC CORP (BSX.DE). This can be considered as Fairly Valued.


Can you provide the profitability details for BOSTON SCIENTIFIC CORP?

BOSTON SCIENTIFIC CORP (BSX.DE) has a profitability rating of 8 / 10.


Can you provide the PE and PB ratios for BSX stock?

The Price/Earnings (PE) ratio for BOSTON SCIENTIFIC CORP (BSX.DE) is 21.29 and the Price/Book (PB) ratio is 3.98.


Can you provide the dividend sustainability for BSX stock?

The dividend rating of BOSTON SCIENTIFIC CORP (BSX.DE) is 0 / 10 and the dividend payout ratio is 0%.